Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

• Status: Unknown status
• Trial end date: 2020-03-20
• Target enrollment: 0
• Participant gender: Male

Summary

In non-small cell lung cancer and metastases in the pleural cavity, pathological effusion is formed.

Currently, the most common and effective method of obliteration of the pleural cavity is pleurodesis with talcum powder.

Talc, when it surface of the pleura, causes chemical inflammation that leads to the soldering of the lungs and chest wall. As a result, the liquid ceases to accumulate.

The addition of a therapeutic dose of afatinib to talc not only blocks effusion into the pleural cavity, but also reduces tumor and metastatic processes.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Center Trials & Treatment Europe
• Collaborator: Center Trials & Treatment
• Treatments: Afatinib

Criteria

Inclusion Criteria:

• Non-small cell lung cancer with positive mutation of EGFR verified

• Malignant pleural effusion

• Recurrent pleural effusion

• Complete lung expansion (> 80%) after puncture emptying confirmed by chest radiography.

• Karnofsky index > 50

• Agreed to participate in the study and sign an Informed Consent

Exclusion Criteria:

• Radiotherapy not earlier than 3 months before the pleurodesis procedure

• Previous surgeries on the same hemitorace

• Thrombocytopenia or coagulation disorders

• Trapped lung syndrome

• Patients with estimated life expectancy < 4-8 weeks

• Pleural or active systemic infection